A Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of PGDM1400LS Alone and in Combination With VRC07-523LS and PGT121.414.LS in Healthy, HIV-uninfected Adult Participants
Public ClinicalTrials.gov record NCT05184452. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Dose-escalation Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of PGDM1400LS Alone and in Combination With VRC07-523LS and PGT121.414.LS in Healthy, HIV-uninfected Adult Participants
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Part A: The purpose of this part of the study is to understand how the body's immune system responds to a new lab-made antibody against HIV. The study is looking to see if the way the antibody is given affects the immune response. The study will also look at whether the antibody is safe to give to people and does not make them too uncomfortable. Part B: The purpose of this part of the study is to understand how the body's immune system responds to lab-made antibodies against HIV when they are given in combination at different doses. The study also wants to see if the way the antibodies are given affects the immune response.
Study identification
- NCT ID
- NCT05184452
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 95 participants
Conditions and interventions
Conditions
Interventions
- PGDM1400LS (5mg/kg, IV) Drug
- PGDM1400LS (20mg/kg, IV) Drug
- PGDM1400LS (20mg/kg, SC) Drug
- PGDM1400LS (40mg/kg, IV) Drug
- PGDM1400LS (40mg/kg, SC) Drug
- PGDM1400LS (1.4g, IV) Drug
- PGDM1400LS (1.4g, SC) Drug
- VRC07-523LS (20mg/kg, IV) Drug
- VRC07-523LS (20mg/kg, SC) Drug
- VRC07-523LS (1.4g, IV) Drug
- VRC07-523LS (1.4g, SC) Drug
- VRC07-523LS (40mg/kg, IV) Drug
- PGT121.414.LS (20mg/kg, IV) Drug
- PGT121.414.LS (20mg/kg, SC) Drug
- PGT121.414.LS (1.4g, IV) Drug
- PGT121.414.LS (1.4g, SC) Drug
- PGT121.414.LS (40mg/kg, IV) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 50 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 14, 2021
- Primary completion
- Jul 18, 2023
- Completion
- Jul 18, 2023
- Last update posted
- Feb 9, 2025
2021 – 2023
United States locations
- U.S. sites
- 5
- U.S. states
- 5
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Bridge HIV CRS | San Francisco | California | 94102 | — |
| George Washington University | Washington D.C. | District of Columbia | 20037-1894 | — |
| The Hope Clinic of the Emory Vaccine Center | Atlanta | Georgia | 30030 | — |
| New Jersey Medical School Clinical Research Center CRS | Newark | New Jersey | 07103 | — |
| Vanderbilt Vaccine (VV) | Nashville | Tennessee | 37232 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.
Recently updated HIV Infections trials
Other public records listing HIV Infections. Sorted by last update posted; newest first. Not a recommendation.
- NCT07650916: A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed Recruiting
- NCT06679751: Infectious Disease (ID) Testing OUtreach in Carceral Hubs Active, not recruiting
- NCT05996471: A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV) Active, not recruiting
- NCT03729778: Impact of HIV-1 and Aging on Mucosal Vaccine Responses Active, not recruiting
- NCT07728123: Screen2Prevent (S2P) Recruiting
- NCT06316739: The Ganchero Intervention for Migrant People Who Inject Drugs From Puerto Rico in New York City Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05184452, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 9, 2025 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05184452 live on ClinicalTrials.gov.